Bridgewater, N.J.-based Cordis is targeted toward “less invasive” treatments for vascular disease, according to the report.
Johnson & Johnson is in the process of removing slower-growth businesses with the ultimate goal of reducing annual costs by $1 billion, according to the report.
The report projects the Cordis sale could bring in between $1.5 billion and $2 billion.
More articles on acquisitions:
Covidien acquires medical device firm Sapheon
Premier to acquire Aperek for $48.5M
5 recent device, biotech company acquisitions
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
